Vineet Laboratories Ltd

NSE: VINEETLAB · Pharmaceuticals · sector

₹37.35NSE close 2026-10-26

Key numbers

Market cap₹35 cr

Price₹37.35

52w high / low₹50 / ₹28

P/E44.5xSector median 27.9x

P/B0.8xSector median 2.9x

Book value₹49.1

Dividend yield–Sector median 0.48%

ROE5.3%Sector median 11.7%

ROCE6.8%Sector median 12.3%

OPM14.3%Sector median 14.0%

Debt / equity0.99xSector median 0.16x

EV/EBITDA7.4xSector median 18.6x

Interest cover1.3x

Current ratio1.47x

Sales growth 3y-34.6%Sector median +9.6%

Profit growth 3y+8.6%Sector median +13.3%

PEG–

Last 12 months to Mar 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹17 cr vs borrowings ₹45 cr (FY26): borrowings are higher by ₹28 cr.
Operating profit covered interest 1.3x in the last 12 months.
Promoter holding fell by 9.91 percentage points in a year, to 5.98% (2026-09-30).
Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY24, FY23).
Net loss in 5 of the last 8 quarters.
Revenue was higher than a year earlier in 1 of the last 4 quarters.
Other income was 6% of net profit in the last 12 months.
Dividend paid in 1 of the last 5 financial years.
Price ₹37.35 on 2026-10-26: -25.3% from the 52-week high, +33.6% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹60.70 · low ₹28.44

Quarterly results

₹ cr	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	24	19	18	14	7	17	16	19
EBITDA	-1	-0	-4	-11	0	3	2	2
OPM %	-3.4%	-1.6%	-22.9%	-78.5%	4.3%	18.3%	15.9%	13.2%
Other income	0	0	0	1	0	0	0	0
Net profit	-2	-2	-6	-11	-1	0	1	1
EPS (₹)	-2.31	-1.98	-6.19	-11.42	-0.94	0.43	0.92	0.43
Revenue YoY					-68.8%	-8.1%	-13.5%	+34.2%
Profit YoY					–	–	–	–

Standalone figures where filed. Latest quarter Mar 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	191	212	151	75	59	59
EBITDA	13	8	7	-16	8	8
Net profit	7	1	1	-20	2	2
EPS (₹)	7.16	1.36	1.11	-21.90	1.00	0.84
Revenue growth		+11.0%	-29.1%	-50.2%	-20.8%	-20.8%
Profit growth		-81.2%	-17.6%	-2,060.2%	–	–
Dividend / share (₹)	–	1.00	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	-34.6%	-24.6%	-20.8%
Net profit	+8.6%	-2.1%	–
EPS	-9.7%	-14.4%	–
Share price	–	-17.5% (2y)	-12.9%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	34	35	15	46
Borrowings	–	31	44	40	45
Cash & equivalents	–	1	0	1	17
Total assets	–	116	117	95	125
Fixed assets	–	27	27	25	24
Capital work in progress	–	0	–	–	0
Investments	–	0	0	0	0
Receivables	–	35	32	13	11
Inventory	–	46	49	50	64
Payables	–	35	32	34	25

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	8	-10	-11	11	-12
Cash from investing	-4	-7	0	-3	-1
Cash from financing	12	0	11	-8	30
Capex	4	8	0	1	1
Free cash flow	4	-17	-12	10	-13

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	3.7%	3.0%	-137.8%	3.5%
ROCE %	–	8.4%	6.5%	-30.7%	6.8%
Debtor days	–	60	77	64	70
Inventory days	–	98	158	260	606
Payable days	–	74	103	175	240
Cash conversion cycle (days)	–	84	132	149	436
Working capital days	–	22	30	-34	194

Shareholding

Holder	% (2026-09-30)
Promoters	5.98%
FIIs	0.24%
Public (non-institutions)	93.78%

Quarter	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Feb 2026	Mar 2026	Jun 2026	Sep 2026
Promoters %	35.85%	29.26%	15.89%	12.46%	5.98%	5.98%	5.98%	5.98%

Promoter group	%
Gaddam Venkata Ramana	2.46%
Satyanarayana Raju Bhupathirajuin30273410069180	0.69%
A Prabhakar Raju	0.50%
A Srinivasa Raju	0.49%
A Ranga Raju	0.39%
Alluri Anantha Laxmi	0.34%
Alluri Mythili	0.29%
Penmetsa Venkata Krishnam Raju	0.25%
P Kishore Raju	0.25%
Gaddam Srinivasarao	0.19%
Gaddam Venkata Rama	0.13%
V Varaprasada Raoin30051319920588	0.01%
Gaddam Balaji	0.01%
Kandula Murali Mohan	0.00%

Public holders above 1%	%
Arjun Aggarwal	9.79%
Mangal Keshav Capital Limited	4.17%
Galaxy Prime Private Limited	2.60%
Madhu Nalajala	2.41%
Rajesh Poddar	2.15%
Rajendra Agrawal	1.57%
Ajay Agrawal	1.53%
Surekha Naga Lakshmi Pendela	1.51%
Sujata Kumari JHA	1.42%
Jyoti Agarwal	1.39%
Suraj Wealth Management Private Limited	1.12%
Charan Reddy Puli	1.08%
Rajeev Makkar	1.05%

9,724 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
VINEETLAB	₹35 cr	44.5x	0.8x	5.3%	6.8%	14.3%	-34.6%	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2025-12-23	Rights	Rights 13:12 @ Premium Rs 20/-
2024-09-17	Other	Annual General Meeting
2023-09-18	Other	Annual General Meeting
2022-09-19	Dividend	Dividend - Re 1 Per Share
2021-09-22	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	VINEETLAB
BSE code	543298
ISIN	INE505Y01010
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.